MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.
Conference details are as follows:
Bell Potter Healthcare Conference | |
Presentation: | Monday, November 18, 2024, 3:00 PM AEDT (Virtual) |
Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com. |
Jefferies London Healthcare Conference 2024 | |
One-on-One Meetings: | Tuesday, November 19, 2024 |
Participant: | Frederic Guerard, PharmD, CEO, Opthea |
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Web: www.opthea.com
Last Trade: | US$3.34 |
Daily Change: | 0.11 3.41 |
Daily Volume: | 15,669 |
Market Cap: | US$513.990M |
December 19, 2024 November 26, 2024 November 15, 2024 November 12, 2024 October 10, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB